INTRODUCTION

Scars remain a challenging clinical problem. Adults often show multiple types of scars in response to trauma, burns, infections or surgery due to the fibrosis that can result from various reasons. The most troublesome pathological types are hypertrophic scars and keloids. A primary difference between these two is that hypertrophic scars are localized within the wound boundary, while keloids will grow beyond the edge of this boundary. Scars can result in both cosmetic and functional discomforts, such as itching or impaired mobility, but can also exert devastating psychologically effects. Such psychological pressure often induces patients to seek effective means to...
beautify or reduce their scars. According to available reports, it has been estimated that up to tens of billions of dollars are expended for treatments and consequences of scars.\textsuperscript{1,4} Despite the application of various methods for the treatment of hypertrophic scars or keloids, the effectiveness of these protocols remains quite limited. Accordingly, a better understanding of the mechanisms involved with scar formation is sorely needed. One potential approach to investigate the root cause of scars involves an examination of this process in the foetus. In the human foetus, a scarless wound repair process is present, a phenomenon that was reported over 30 years ago.\textsuperscript{5} Subsequent studies have revealed that this scarless wound repair depends on age and that there is a transition from a scar-free to scar formation process that occurs in the later period of foetal development. This transition occurs at around 24 weeks in human pregnancy and at day 18 of gestation in mice.\textsuperscript{6,7} This extraordinary ability for the initial prevention of scar formation followed by a transition to a scar formation process in the foetus suggests that adult skin may also possess a similar mechanism, which could be activated to reduce adult scar formation like that observed in the foetus.

The molecular basis of scarless wound healing in mammalian foetuses has been partially reported before,\textsuperscript{8} but research on the basis of small rodent models has not been comprehensively sorted out. In this review, we summarized research mainly in the recent years on the healing mechanisms as observed in the foetus and adult from the perspective of tissues, cells and molecules, and explored the possibility of applying these findings to scar treatment. We focused on the wound healing process within the foetal model due to its remarkable capacity for scarless healing and evaluated the advantages and disadvantages that can be garnered from this model. Compared with the previous review,\textsuperscript{9} up-to-date findings on foetal skin and adult scars using gene sequencing technology, and mechanisms of various non-coding RNAs in the formation of scars and their potential application for clinical treatment are also included in this review. Differences in tissue structure, cell types and molecules between foetal wound and adult wound are briefly illustrated in Figure 1.

2 | EVOLUTION OF THE FOETAL WOUND MODEL

Since the initial discovery of foetal skin regeneration, a variety of animal wound healing models have been developed, including lamb, monkey, rabbit and opossum, with the goal that these models will provide an understanding of the mechanisms involved in this regeneration process.\textsuperscript{10-12} As one example, Stelnicki and colleagues used foetal lambs to evaluate the neural dependence of scarless healing after denervation.\textsuperscript{13} Although these large animal models are technically more advantageous, the expenses involved severely limit their use in these experiments. The substantially lower costs and shorter gestations of rats and mice, along with well-identified genomes and transgenic technology that can be used to examine loss or gain of function in mice account for the preferential use of these rodent models.

A considerable amount of valuable information has been obtained from in vitro experiments using major functional cell lines of

---

Figure 1 Differences and components involved in the repair process of foetal mice and adult mice after wound modelling.
keratinocytes and fibroblasts subjected to injury. However, a major deficit in these studies was their failure to include all components of the skin and lack of assessing these injury responses in an in vivo environment. Therefore, the development of an effective in vivo wound healing model is required for exploring the complex mechanisms involved with these responses.

In 1992, a graft of human foetal skin was observed to demonstrate scar-free wound healing when applied onto the skin of mice. In this study, the amniotic fluid environment was not a necessary condition for this scar-free regeneration of foetal skin. These findings provided the feasibility and foundation for the development of in vivo models to study foetal injury repair in mammals. One of the first attempts was that of Stelnicki and colleagues in 1997 and involved use of incisional wounds on the hind limbs of 14-day-old mice; however, the limited nature of their incision failed to affect the integrity of the skin in these mice, thus preventing an assessment of the healing process of this dermal deficiency. Over the next ten years, a number of in vivo models of excisional wounds were developed with a rat model in 2002 and the first in vivo excisional mouse model in 2006. The recent scar-free wound healing model using foetal mice has been updated with the protocol of timed superovulation, while emphasizing the importance of amniotic fluid supplementation during surgery. In Figure 2, we show the exploration of foetal wound healing models, especially rat and mouse models, in the above-mentioned time sequence since the 1990s.

### 3. COMPARISON BETWEEN FOETAL AND ADULT SKIN WOUND REPAIR

#### 3.1 From macro to histological levels

Over the years, there have been a substantial number of studies directed at examining various aspects of tissue samples after foetal damage. In Table 1, we summarize the studies using the in vivo rat and mouse wound models that have been used to unearth the mechanisms of foetal skin regeneration. Needless to say there are an extensive number of genes differentially expressed during foetal development, regardless of whether the foetus is damaged or not. With the maturation of gene sequencing technology, the mechanisms by which non-coding RNAs participate in this process have also emerged. For example, dicer, the key enzyme for miRNA synthesis, is significantly increased in late embryonic tissue. Particularly interesting mouse model of relevance to this review is the African spiny mouse (Acomys), which shows regenerative responses in their skin following damage. These regenerative responses show a similar phenotype to that of the wound healing observed in the foetus with lower levels of inflammatory responses and no significant excessive amounts of collagen secretion. When compared to normal mice, Acomys show differences in expression levels of phosphorylation-related proteins, macrophage markers and immunomodulators after injury. Ubiquitination and phosphorylation are major mechanisms significantly enhanced in protein synthesis and degradation. Cellular and molecular differences after foetal injury will be discussed below.

#### 3.2 Key roles of fibroblasts

Fibroblasts represent one of the most critical cells that participate in the entire process of wound repair through their effects on proliferation, differentiation, synthesis of collagen, interactions with other cells and their capacity to form different fibrotic environments in various organs. Results obtained using sophisticated cell isolation methods have revealed that enormous differences in gene expressions within fibroblasts are present between the mid- and late-gestational periods in mice. These changes in fibroblasts at different developmental stages suggest that they may be closely related to the distinct responses observed after injury at these times, as related to the accompanying activation and inhibition of multiple pathways. Cyclooxygenase 1 was one of the 12 differentially expressed inflammatory genes, which was expressed at higher levels in E18 versus E15 fibroblasts. When comparing human foetal versus adult dermal fibroblasts, as achieved with use of protein expression profiling, it was found that the heat-shock cognate 71 kDa protein, which is active in organism survival, and tubulin alpha-1A
chain, a vital component of cell cytoskeleton, both showed greater expressions in foetal fibroblasts that conceivably account for the rapid regeneration of foetus, whereas cofilin-1 and peroxiredoxin-1 were expressed at comparatively higher concentrations in adult fibroblasts.47

An area of investigation that has attracted considerable attention of late is that of research on fibroblast heterogeneity and the tracking of different fibroblast lineages. It seems clear that distinct lineages can play diverse roles at different stages of skin development. For example, the reticular fibroblasts located in the lower portions of the dermis are responsible for synthesizing extracellular matrix and begin to repair immediately after injury. In contrast, papillary fibroblasts in the upper portion of the dermis regulate hair follicular formation and may be related to the loss of regional hair follicles after adult injury and play a role in the later stages of wound healing.48,49 As based on the gene, engrailed 1 (En1), which is expressed in embryonic cells, two related fibroblast cell lines have been identified, En1-lineage-past fibroblasts

### TABLE 1
Summary of studies using the in vivo rat and mouse wound models

| Scientists of study | Rat or mice; wound model | Time points of evaluation | Differentially expressed genes | Change trends of expression |
|---------------------|--------------------------|--------------------------|--------------------------------|---------------------------|
| Soo et al (2000)    | Foetal rat; 2 mm full-thickness excisional wounds | 12, 36 and 72 h post-wounding | Fibromodulin | Fibromodulin is up-regulated in E16 rather than 19 wounds |
| Dang et al (2003)   | Foetal rat; 2 mm full-thickness excisional wounds | 24, 48 and 72 h post-wounding | MMP; TIMP | Greater MMP relative to TIMP expressed in E16 than E19 |
| Traci et al (2004)  | Foetal mice; 2 mm full-thickness incisional wounds | 6, 24 h and 7 d post-wounding | COX-2; PGE2 | COX-2 and PGE2 higher in E18 wound tissue than E15 |
| Colwell et al (2006) | Foetal mice; 1 mm full-thickness excisional wounds | 8, 12 and 24 h post-wounding | Lysyl oxidase | More lysyl oxidase in E19 compared with E17 wounds |
| Goldberg et al (2007) | Foetal mice; 3 mm full-thickness excisional wounds | 32 h post-wounding | TGF-β1; TβR-2 | TGF-β1 and TβR-2 increasing in rapid foetal wound closure |
| Goldberg et al (2007) | Foetal mice; 3 mm full-thickness excisional wounds | 32, 48 and 72 h post-wounding | Procollagen types 1α2 and 3 | Procollagen types 1α2 and 3 increased in E15 compared with the E18 |
| Traci et al (2008)  | Foetal mice; 2 mm full-thickness incisional wounds | 7 d post-wounding | VEGF | Higher levels of VEGF in E18 than that in E15 |
| Colwell et al (2008) | Foetal mice; 1 mm full-thickness excisional wounds | 1, 12 and 24 h post-wounding | Genes detected by genomic microarray | Most of genes up-regulated at 1 or 12 hours after injury in E17 compared with adult |
| Carter et al (2009) | Foetal mice; 2.5 mm full-thickness excisional wounds | 15 and 45 min post-wounding | Cleaved caspase 7; cleaved PARP | Cleaved caspase 7 and cleaved PARP increasing more in E15 than in E18 |
| Antony et al (2010) | Foetal rat; 2 mm full-thickness excisional wounds | 24 and 72 h post-wounding | Genes detected by macroarray | Many neurodevelopmental genes up-regulated in E16 |
| Dardenne et al (2013) | Foetal mice; 2 mm full-thickness incisional wounds | Ranging from 2 h to 7 d post-wounding | Alarmin HMGB-1 | More HMGB-1 expressed in E18 compared with E15 |
| Zheng et al (2016)  | Foetal rat; 2 mm full-thickness excisional wounds | 72 h post-wounding | Fibromodulin; TGF-β1 | Fibromodulin reduces TGF-β1 expression in E18 wounds |
| Hu et al (2018)     | Foetal mice; 1 mm full-thickness excisional wounds | 1, 12 and 24 h | Pathway analysis of genes detected by microarray | Top 20 identified signalling pathways up-regulated and down-regulated at 1 and 12 h after injury; 11 up-regulated pathways after 24 h |
| Wulff et al (2019)  | Foetal mice; 2 mm full-thickness incisional wounds | Ranging from 2 h to 7 d post-wounding | Alarmin IL-33 | Higher level of IL-33 expressed in E18 wounds compared with E15 |
(EPFs) and En1-lineage-naive fibroblasts (ENFs). Interestingly, these two cell lines exert markedly different effects upon scar formation, with EPFs primarily contributing to the formation of pathological scars, while ENFs are not involved in this process but are closely related to dermal development and regeneration. The number of ENFs gradually decreases with development, which is in line with the decline in regeneration effects and the increase in scar formation as observed in response to damage at later stages of embryonic development. More interestingly, the scarring effect of EPFs can be reversed by localized treatments of ENFs.

During wound healing, myofibroblasts, derived from the differentiation of fibroblasts, play a role in the synthesis of ECM and tissue contraction. It has been reported that foetal skin wounds lack myofibroblasts; however, application of TGF-β on human foetal fibroblasts cultured in vitro induced cells, which obtained similar characteristics to myofibroblasts. Strangely, myofibroblasts, which have always been considered as fully differentiated cells, can aid in fat reconstruction. When single-cell sequencing technology was utilized to detect the presence of 12 heterogeneous fibroblasts in the wounded skin of adult mice, a subcluster of fibroblasts derived from bone marrow was found. Results, as observed with bone marrow transplantation technology, have demonstrated that bone marrow haematopoietic cell lines can generate myofibroblasts and regenerate adipocytes, which may be related to the dilemma of fat regeneration after trauma.

## 3.3 Differences in keratinocytes

As a critical component of the epidermis, keratinocytes secrete keratin filaments to participate in the keratinization and protection of skin from the invasion of external microorganisms. Of particular significance to the present review, keratinocytes also undertake the major mission of re-epithelization and wound closure after skin damage and are a key factor in the delay of wound healing in adults. Pastar and colleagues reported some notable changes that occur in keratinocyte genes during embryonic development with 24 genes being down-regulated in keratinocytes at E16 as compared to E18 and no obvious evidence for any genes being up-regulated. In E18 keratinocytes, specifically up-regulated β-catenin-dependent Wnt pathways were demonstrated to play a key role in the scarring process of late-gestational age. In contrast, focal adhesion kinase (FAK) was previously manifested a close connection with mechanotransduction and fibrosis. Interestingly, keratinocyte FAK-deleted mice were found to obtain thinner skin and lessened collagen density, while FAK-deleted keratinocytes actively participated in mechanotransduction and extracellular matrix production, by overexpressing Igfbl, Mmpia and Col4a1.

Receptor-interacting protein kinase 4 (RIPK4) and interferon regulatory factor 6 (IRF6) both play a vital role in the differentiation of keratinocytes, with mutations in either of these two having the potential of resulting in epidermal developmental disorders. As compared to that observed in RIPK4 full knockout mice, in neonatal mice with a specific removal of RIPK4 in keratinocytes, the epidermis shows a normal structure, but the lack of a skin barrier function leads to accelerated water loss and severely limits the lifespan of these newborns. IRF6 interacts with the AP2P protein and MCS9.7 enhancer to form a regulatory network, which together guides epidermal development and is a risk factor associated with orofacial clefts. IRF6 also appears to be involved with the capacity for epidermal progenitor cells to produce regeneration in portions of sweat glands after burns. In addition to their individual effects, these two factors interact with each other as RIPK4 can regulate IRF6 to alter the expression of downstream transcription factors, which forms an axis in the protein kinase C pathway to guide the differentiation of keratinocytes. This axis, in turn, boosts inflammation within the epidermis by inducing an excessive production of pro-inflammatory keratinocyte cytokines, such as CCL5 and CXCL11. With the use of RNA-seq, ChIP-seq and ATAC-seq, Oberbeck and colleagues have demonstrated the gene enrichment present in IRF6 knockout foetal mice during development, along with the general and histological differences in these mice as compared to normal controls. As compared to that observed in adults, human foetal keratinocytes expand faster, show properties similar to that of stem cells and were induced to demonstrate an orderly differentiation as demonstrated in vitro. These findings suggest that human foetal keratinocytes can be used as bioengineering material for cell transplantation to assist in wound healing.

## 3.4 Other cells emerging to be targeted

In addition to fibroblasts and keratinocytes, there exist a number of other molecules and cells that show contrasting temporospatial characteristics and expressions in wound responses between the adult and foetus. For example, observations from immunofluorescence have revealed that human foetal skin contains significantly reduced amounts of immune cells and chemokines, such as macrophages, mast cells, CCL17 and CCL21, as compared to that observed in adult skin. The number of leucocytes marked by CD45 is reduced in portions of sweat glands after burns. In addition to these components of foetal skin that can modulate this wound healing process, the amniotic fluid, cord blood and amniotic membrane present during pregnancy contain a rich source of stem cells, which can also contribute to the repair and scar-suppressing effects. Both mesenchymal stem cells, derived from human umbilical cord blood (UCB-MSCs), and stem cells, derived from human amniotic fluid (hAFS), enable adult injuries to acquire foetal-like repair processes, which were respectively characterized...
| miRNA       | Scientists of study | Correlation with scar growth | Targets involved                  | Effect                                                                                       |
|-------------|---------------------|------------------------------|----------------------------------|--------------------------------------------------------------------------------------------|
| miR-29b     | Guo et al (2017)    | Negative                     | TGF-β1, Smad, CTGF               | In vivo: reduces inflammation, collagen synthesis and deposition                             |
| miR-495     | Guo et al (2019)    | Negative                     | FAK                              | In vitro: reduces fibroblast proliferation and enhances apoptosis                            |
| miR-98      | Bi et al (2017)     | Negative                     | Col1A1                           | In vitro: reduces fibroblasts viability and enhances apoptosis                              |
| miR-149     | Lang et al (2017)   | Negative                     | IL-1α, IL-1β, IL-6, TGF-β3, Col3 | In vitro: reduces inflammatory factor expression in HaCaTs                                    |
| miR-143-3p  | Mu et al (2016)     | Negative                     | CTGF                             | In vitro: reduces ECM synthesis including Col1, Col3 and α-SMA and reduces fibroblasts proliferation in the Akt/mTOR pathway |
| MicroRNA Seq-915_x4024 | Zhao et al (2019) | Negative                     | Sar1A, Smad2, TNF-α, IL-8        | In vitro: enhances keratinocyte proliferation and migration and reduces inflammation In vivo: reduces inflammatory cell infiltration and scar size |
| miR-519d    | Zhou et al (2018)   | Negative                     | SIRT7                            | In vitro: reduces fibroblast proliferation and ECM synthesis including Col1, Col3 and α-SMA and enhances apoptosis |
| miR-145-5p  | Shen et al (2020)   | Negative                     | Smad2, Smad3                     | In vitro: reduces fibroblast proliferation and migration In vivo: reduces inflammation and fibrosis |
| miR-145     | Zhu et al (2015)    | Negative                     | Smad3                            | In vitro: gene up-regulated by PPAR-gamma agonist reduces collagen synthesis                  |
| miR-145     | Gras et al (2015)   | Positive                     | Col1A1, TGF-β1                   | In vitro: regulates differentiation from fibroblast to myofibroblasts, enhances myofibroblast viability and migration. |
| miR-6836-3p | Liu et al (2018)    | Positive                     | CTGF                             | In vitro: enhances fibroblast proliferation and reduces apoptosis                           |
| miR-21      | Guo et al (2017)    | Positive                     | COI1A1, COI1A2, fibronectin      | In vitro: enhances fibroblast proliferation and reduces apoptosis In vivo: antagonim reduces collagen deposition and scar size |
| miR-181b    | Kwan et al (2015)   | Positive                     | Decorin                          | In vitro: regulates differentiation from fibroblast to myofibroblasts                      |
| miR-192     | Li et al (2017)     | Positive                     | SIP1                             | In vitro: enhances ECM synthesis including Col1, Col3 and α-SMA In vivo: enhances collagen synthesis |
| miR-181b-5p | Liu et al (2019)    | Positive                     | Decorin                          | In vitro: enhances fibroblast proliferation and reduces apoptosis in the MEK/ERK/p21 pathway |
| miR-152-3p  | Wang et al (2019)   | Positive                     | FOXF1                            | In vitro: enhances fibroblast proliferation and ECM synthesis including Col1, Col3 and fibronectin |
| miRNA-1908  | Xie et al (2016)    | Positive                     | Scar suppressor Ski              | In vitro: enhances fibroblast proliferation and pro-inflammation In vivo: increases scar size |
| miR-155     | Velazquez et al (2017) | Positive                  | IL-1β, TNF-α, IL-10, α-SMA, Col1, Col3 | In vivo: gene knockout reduces inflammation and ECM synthesis including Col1, Col3 and α-SMA without healing time compensation |
by reduced level of inflammatory cytokine expressed by UCB-MSCs and closely analogous collagen type III proportion to that of the foetal wound triggered by hAFs. Simultaneously, exosomes, as part of the paracrine activity of stem cells, also promote wound healing and limit scar formation.87,88 Recent evidence indicates that peripheral cells play a role in scar formation and regulation of vascular regeneration.89 As peripheral cell therapy has been shown to reduce the accumulation of inflammatory cells and organize collagen in remodelling phases, this suggests one possible mechanism for this effect of peripheral cells in this scar formation.90

4 | INVOLVEMENT OF DIVERSE MOLECULES

4.1 | Proteins displaying key functions

In foetal sheep, a diverse array of molecular responses has been observed in response to wounds and trauma. For example, IL-10 effectively reduces the number of inflammatory cells and significantly lessened scars at the location of a severe trauma.91 IL-4Rα–activated macrophages participate in the fibrosis process and up-regulate the expression and deposition of collagen fibres through the continuous secretion of lysine hydroxylase 2 in fibroblasts.92 The plasminogen activator inhibitor type 1 (PAI1), secreted by keratinocytes, stimulates intercellular crosstalk between fibroblasts and mast cells in adhesions, which likely contributes to scleroderma.93 As demonstrated both in vivo and in vitro, inhibition of calpain constrains granulation tissue growth by reducing collagen synthesis.94 As peripheral cell therapy has been shown to reduce the accumulation of inflammatory cells and organize collagen in remodelling phases, this suggests one possible mechanism for this effect of peripheral cells in this scar formation.90

4.2 | Non-coding RNAs implicated in dermal fibrosis

Along with this research focusing on proteins, in recent years, the emergence of non-coding RNAs, which actively participate in every stage of wound healing, has also attracted a considerable amount of attention.9 Gene therapy involved with the application of non-coding RNAs will inevitably represent a major breakthrough in the clinical treatment of various diseases. With regard to skin fibrosis, the mechanisms responsible for the extreme hyperplastic scar and keloid in trauma sequelae are closely related to non-coding RNAs, in particular miRNA and lncRNA. Accordingly, the mechanisms of non-coding RNA involvement in scar development and their prospects for being targeted in clinical treatment warrant discussion.

4.2.1 | Effects of miRNAs on scar formation

miRNAs are small molecules of approximately 22-nucleotide lengths, which target the inhibition of mRNA translation. Interestingly, miRNAs are characterized by dynamic changes during embryonic development and usually suppress expression of factors in foetal wounds.99 In Table 2, we present a summary of research primarily focused on the impact of miRNAs in scar formation during the adult stage.100-120 Differentially expressed miRNAs have been detected between scar lesions in adult versus embryonic skin.121 Such discriminatory responses in core miRNAs as related to scar development after injury suggest promising new targets for clinical treatment.

| miRNA | Scientists of study | Correlation with scar growth | Targets involved | Effect |
|-------|---------------------|-----------------------------|-----------------|--------|
| miR-130a | Zhang et al (2019) | Positive | CYLD | In vitro: enhances fibroblast proliferation and ECM synthesis including Col1, Col3 and α-SMA in the Akt pathway In vivo: gene inhibitor reduces collagen deposition |
| miR-203 | Zhou et al (2018) | Positive | Hes1 | In vitro: promotes differentiation from ESCs to myofibroblasts In vivo: accelerates healing and reduces scar size |
| miRNA-21, miRNA-141-3p, miRNA-181a, miRNA-205 | Lyu et al (2019) | Positive | – | In vitro: enhances fibroblast proliferation and reduces apoptosis in the TGF-β/Smad3 pathway |
| miRNA-637, miRNA-1224 | Lyu et al (2019) | Negative | – | In vitro: enhances fibroblast proliferation and reduces apoptosis in the TGF-β1/Smad3 pathway |
4.2.2 Complex mechanisms of IncRNAs

The mechanisms of long non-coding RNAs are more intriguing, but complicated, and have recently been widely investigated in the pathogenesis of skin fibrosis, especially in hypertrophic scars and keloids. Based on results obtained with modern gene sequencing or chips, a number of IncRNAs have been identified, which could serve as biomarkers in the course of various diseases; however, their mechanisms remain unclear. Moreover, through in vitro loss-of-function or gain-of-function experiments, it is possible to distinguish IncRNAs that promote or inhibit the development of hypertrophic scars or keloids.

The sponging effect of IncRNAs on miRNAs forms an axis that determines the downstream mRNA expression. These axes including IncRNA-ATB/miR200c/TGF-β2, IncRNA XISt/miR-29b-3p, IncRNA HOXA11-AS/miR124-3p/TGF-β1R1 and IncRNA-H19/miR-29a/Col1A1 have been shown to promote pathogenesis in vitro, through enhancing fibroblasts of vitality, proliferation and migration or by ECM synthesis while inhibiting apoptosis. In contrast, the axes IncRNA COI1A2-AS1/miR-21/smad7, IncRNA 8975-1 and IncRNA AC067945.2 inhibit scar formation through exerting opposite effects on fibroblast pathological changes and collagen synthesis as that observed in scar formation. Moreover, in cell co-culture experiments, IncRNA ASLNC5088 exosomes as secreted from M2 cells endogenously bind miR-200c-3p, thus promoting fibroblast differentiation and pathological function, an effect which can be reversed by GW4869. As these complicated functions of IncRNAs are gradually revealed, their application and effectiveness in the treatment of hypertrophic scars and keloids will be realized.

5 CONCLUSIONS

Research on scarless wound healing and scar reduction has been ongoing for decades, with innovative techniques and in vitro and in vivo models used to identify numerous cells, factors and novel genes related to this process. Armed with this information, as well as findings from future studies, effective clinical treatment, such as targeted drugs for key molecules or the development of engineered cells, will gradually be revealed. However, the complex and overlapping pathways may require more investigations on the regulation mechanisms of genes with unidentified functions. Newly emerging technologies focusing on detection of non-coding RNA, single-cell transcriptome and RNA methylation can be regarded as a breakthrough in further exploration of unknown areas. Even if the impeccable regeneration of foetal skin cannot be fully exerted in clinical practice, at present, we feel this review will promote the evolution of this process to bring new perspectives for future treatment and cosmetology.

CONFLICTS OF INTERESTS

The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

Jia-Li Yin involved in writing—original draft preparation. Jia-Li Yin, Yan Wu, Zheng-Wei Yuan and Xing-Hua Gao involved in writing—review and editing. Zheng-Wei Yuan and Xing-Hua Gao involved in visualization. Xing-Hua Gao and Hong-duo Chen involved in supervision, project administration and funding acquisition.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Xing-Hua Gao https://orcid.org/0000-0001-8809-8564

REFERENCES

1. Brown BC, McKenna SP, Siddhi K, et al. The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg. 2008;61(9):1049-1058.
2. Tyack Z, Ziviani J, Kimble R, et al. Measuring the impact of burn scarring on health-related quality of life: development and preliminary content validation of the Brisbane Burn Scar Impact Profile (BBSIP) for children and adults. Burns. 2015;41(7):1405-1419.
3. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43(Suppl 1):S3-s18.
4. Gurtner GC, Werner S, Barrandon Y, et al. Wound repair and regeneration. Nature. 2008;453(7193):314-321.
5. Longaker MT, Adzick NS. The biology of fetal wound healing: a review. Plast Reconstr Surg. 1991;87(4):788-798.
6. Cass DL, Bullard KM, Sylvester KG, et al. Wound size and gestational age modulate scar formation in fetal wound repair. J Pediatr Surg. 1997;32(3):411-415.
7. Colwell AS, Krummel TM, Longaker MT, et al. An in vivo mouse excisional wound model of scarless healing. Plast Reconstr Surg. 2006;117(7):2292-2296.
8. Kathju S, Gallo PH, Satish L. Scarless intregumentary wound healing in the mammalian fetus: molecular basis and therapeutic implications. Birth Defects Res C Embryo Today. 2012;96(3):223-236.
9. Luan A, Hu MS, Leavitt T, et al. Noncoding RNAs in wound healing: a new and vast frontier. Adv Wound Care (New Rochelle). 2018;7(1):19-27.
10. Adzick NS, Longaker MT. Animal models for the study of fetal tissue repair. J Surg Res. 1991;51(3):216-222.
11. Longaker MT, Dodson TB, Kaban LB. A rabbit model for fetal cleft lip repair. J Oral Maxillofac Surg. 1990;48(7):714-719.
12. Longaker MT, Stern M, Lorenz HP, et al. A model for fetal cleft lip repair in lambs. Plast Reconstr Surg. 1992;90(5):750-756.
13. Stelnicki EJ, Doolabh V, Lee S, et al. Nerve dependency in scarless fetal wound healing. Plast Reconstr Surg. 2000;105(1):140-147.
14. Bartold PM, Raben A. Growth factor modulation of fibroblasts in simulated wound healing. J Periodontal Res. 1996;31(3):205-216.
15. Ibara S, Motobayashi Y, Nagao E, Kistler A. Ontogenetic transition of wound healing pattern in rat skin occurring at the fetal stage. Development. 1990;110(3):671-680.
16. Lackler KP, Cochran DL, Mai Hoang A, et al. Development of an in vitro wound healing model for periodontal cells. J Periodontol. 2000;71(2):226-237.
17. Chen W, Fu X, Ge S, et al. Profiling of genes differentially expressed in a rat of early and later gestational ages with high-density oligonucleotide DNA array. Wound Repair Regen. 2007;15(1):147-155.
18. Iocono JA, Ehrlich HP, Keefer KA, et al. Hyluronan induces scarless repair in mouse limb organ culture. J Pediatr Surg. 1998;33(4):564-567.

19. Lorenz HP, Longaker MT, Perkocha LA, Jennings RW, Harrison MR, Adzick NS. Scarless wound repair: a human fetal skin model. Development. 1992;114(1):253-259.

20. Stelnicki EJ, Bullard KM, Harrison MR, et al. A new in vivo model for the study of fetal wound healing. Ann Plast Surg. 1997;39(4):374-380.

21. Beanes SR, Hu F-Y, Soo C, et al. Confocal microscopic analysis of scarless repair in the fetal rat: defining the transition. Plast Reconstr Surg. 2002;109(1):160-170.

22. Soo C, Hu F-Y, Zhang X, et al. Differential expression of fibromodulin, a transforming growth factor-β modulator, in fetal skin development and scarless repair. Am J Pathol. 2000;157(2):423-433.

23. Wulff BC, Yu L, Parent AE, et al. Novel differences in the expression of inflammation-associated genes between mid- and late-gestation dermal fibroblasts. Wound Repair Regen. 2013;21(1):103-112.

24. Dang CM, Beanes SR, Lee H, et al. Scarless fetal wounds are associated with an increased matrix metalloproteinase/tissue-degenerate inhibitor of metalloproteinase ratio. Plast Reconstr Surg. 2003;111(7):2273-2285.

25. Wilgus TA, Bergdall VK, Tober KL, et al. The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing. Am J Pathol. 2004;165(3):753-761.

26. Colwell AS, Longaker MT, Peter Lorenz H. Identification of developmental genes during scarless fetal wound repair. Am J Pathol. 2005;167(1):209-220.

27. Goldberg SR, Quirk GL, Sykes VW, et al. Altered procollagen gene expression in mid-gestational mouse excisional wounds. J Surg Res. 2007;143(1):27-34.

28. Wilgus TA, Ferreira AM, Oberytsyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88(6):579-590.

29. Colwell AS, Longaker MT, Peter Lorenz H. Identification of differentially regulated genes in fetal wounds during regenerative repair. Wound Repair Regen. 2008;16(3):450-459.

30. Carter R, Sykes V, Lanning D. Scarless fetal mouse wound healing may initiate apoptosis through caspase 7 and cleavage of PARP. J Surg Res. 2009;156(1):74-79.

31. Antony AK, Kong W, Lorenz HP. Uregulation of neurodevelopmental genes during scarless healing. Ann Plast Surg. 2010;64(2):247-250.

32. Dardenne AD, Wulff BC, Wilgus TA. The alarmin HMGB-1 influences healing outcomes in fetal wounds. Wound Repair Regen. 2013;21(2):282-291.

33. Zheng Z, Zhang X, Dang C, et al. Fibromodulin is essential for fetal-type scarless cutaneous wound healing. Am J Pathol. 2016;186(11):2824-2832.

34. Hu MS, et al. Pathway analysis of gene expression in murine fetal and adult wounds. Adv Wound Care (New Rochelle). 2018;7(8):262-275.

35. Wulff BC, Pappa NK, Wilgus TA. Interleukin-33 encourages scar formation in murine fetal skin wounds. Wound Repair Regen. 2019;27(1):19-28.

36. Cheng J, Yu H, Deng S, et al. MicroRNA profiling in mid- and late-gestational fetal skin: implication for scarless wound healing. Tohoku J Exp Med. 2010;221(3):203-209.

37. Seifert AW, Kiama SG, Seifert MG, et al. Skin shedding and tissue regeneration in African spiny mice (Acomys). Nature. 2012;489(7417):561-565.

38. Brant JO, Lopez M-C, Baker HV, et al. A comparative analysis of gene expression profiles during skin regeneration in mus and acomys. PLoS One. 2015;10(11):e0142931.

39. Brant JO, Yoon JH, Polvadoro T, Barbazuk WB, Maden M. Cellular events during scar-free skin regeneration in the spiny mouse, acomys. Wound Repair Regen. 2016;24(1):75-88.

40. Yoon JH, Cho K, Garrett TJ, et al. Comparative proteomic analysis in scar-free skin regeneration in acomys cahirinus and scarring musculus. Sci Rep. 2020;10(1):166.

41. Larson BJ, Longaker MT, Lorenz HP. Scarless fetal wound healing: a basic science review. Plast Reconstr Surg. 2010;126(4):1172-1180.

42. Mah W, Jiang G, Olver D, et al. Elevated CD26 expression by skin fibroblasts distinguishes a profibrotic phenotype involved in scar formation compared to gingival fibroblasts. Am J Pathol. 2017;187(8):1717-1735.

43. Wulff BC, Yu L, Parent AE, et al. Novel differences in the expression of inflammation-associated genes between mid- and late-gestation dermal fibroblasts. Wound Repair Regen. 2013;21(1):103-112.

44. Hu MS, Borrelli MR, Januszyk M, et al. Pathway analysis of gene expression of E14 versus E18 fetal fibroblasts. Adv Wound Care (New Rochelle). 2018;7(1):1-10.

45. Hay S, Marcal H, Foster LJ. Towards scarless wound healing: a comparison of protein expression between human, adult and foetal fibroblasts. Biomed Res Int. 2014;2014:676493.

46. Driskell RR, Lichtenberger BM, Hoste E, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature. 2013;504(7479):277-281.

47. Nauroy P, Barruche V, Marchand L, et al. Human dermal fibroblast subpopulations display distinct gene signatures related to cell behaviors and matrisome. J Invest Dermatol. 2017;137(8):1787-1789.

48. Rinkevich Y, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015;348(6232):p. aaa2151.

49. Jiang D, Correa-Gallegos D, Christ S, et al. Two succeeding fibroblast lineages drive dermal development and the transition from regeneration to scarring. Nat Cell Biol. 2018;20(4):422-431.

50. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27(5):549-550.

51. Walraen M, Akershoek JJ, Beelen RH, Ulrich MM. In vitro cultured fetal fibroblasts have myofibroblast-associated characteristics and produce a fibrotic-like environment upon stimulation with TGF-beta1: Is there a thin line between fetal scarless healing and fibrosis? Arch Dermatol Res. 2017;309(2):111-121.

52. Plikus MV, Guerrero-Juarez CF, Ito M, et al. Regeneration of fat cells from myofibroblasts during wound healing. Science. 2017;355(6326):748-752.

53. Guerrero-Juarez CF, Dedhia PH, Jin S, et al. Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. Nat Commun. 2019;10(1):650.

54. Braguilla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat. 2009;214(4):516-559.

55. Pastar I, Stojadinovic O, Yin NC, et al. Epithelialization in wound healing: a comprehensive review. Adv Wound Care. 2014;3(7):445-464.

56. Liarte S, Bernabe-Garcia A, Nicolas FJ. Role of TGF- in skin chronic wound healing. Experientia. 1971;27(5):549-550.

57. Pastar I, Stojadinovic O, Yin NC, et al. Epithelialization in wound healing: a comprehensive review. Adv Wound Care. 2014;3(7):445-464.

58. Liarte S, Bernabe-Garcia A, Nicolas FJ. Role of TGF- in skin chronic wound healing. Experientia. 1971;27(5):549-550.

59. Wong VW, Garg RK, Sorkin M, et al. Loss of keratinocyte focal adhesion kinase stimulates dermal proteolysis through upregulation of MMP9 in wound healing. Ann Surg. 2014;260(6):1138-1146.

60. Januszky M, Kwon S, Wong V, et al. The role of focal adhesion kinase in keratinocyte fibrogenic gene expression. Int J Mol Sci. 2017;18(9):1915.
62. Rountree RB, Willis CR, Dinh H, et al. RIP4 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol. 2010;130(1):102-112.

63. Biggs LC, Rhea L, Schutte BC, et al. Interferon regulatory factor 6 is necessary, but not sufficient, for keratinocyte differentiation. J Invest Dermatol. 2012;132(2):50-58.

64. Ingraham CR, Kinoshita A, Kondo S, et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet. 2006;38(11):1335-1340.

65. Richardson RJ, Dixon J, Malhotra S, et al. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat Genet. 2006;38(11):1329-1334.

66. Kalay E, Sezgin O, Chellappa V, et al. Mutations in RIPK4 cause the autosomal-recessive form of popliteal pterygium syndrome. Am J Hum Genet. 2012;90(1):76-85.

67. Kondo S, Schutte BC, Richardson RJ, et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet. 2002;32(2):285-289.

68. Mitchell K, O’Sullivan J, Missero C, et al. Exome sequence identifies RIPK4 as the Bartosca-Papas syndrome locus. Am J Hum Genet. 2012;90(1):69-75.

69. De Groote P, Tran HT, Fransen M, et al. A novel RIPK4-IRF6 connection is required to prevent epithelial fusions characteristic for popliteal pterygium syndromes. Cell Death Differ. 2015;22(6):1012-1024.

70. Urvyler-Rösselet C, Tanghe G, Leurs K, et al. Keratinocyte-specific ablation of RIPK4 allows epidermal cornification but impairs skin barrier formation. J Invest Dermatol. 2018;138(6):1268-1278.

71. Kousa YA, Fuller E, Schutte BC, et al. IRF6 and AP2A interaction regulates epidermal development. J Invest Dermatol. 2018;138(12):2578-2588.

72. Yao B, Song W, Li Z, et al. Irf6 directs glandular lineage differentiation of epidermal progenitors and promotes limited sweat gland regeneration in a mouse burn model. Stem Cell Res Ther. 2018;9(1):179.

73. Kwa MQ, Huynh J, Aw J, et al. Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation. J Biol Chem. 2014;289(45):31077-31087.

74. Kwa MQ, Scholz GM, Reynolds EC. RIPK4 activates an IRF6-mediated proinflammatory cytokine response in keratinocytes. Cytokine. 2016;83:19-26.

75. Oberbeck N, Pham VC, Webster JD, et al. The RIPK4-IRF6 signaling axis safeguards epidermal differentiation and barrier function. Nature. 2019;574(7777):249-253.

76. Tan K, Salgado G, Connolly J, et al. Characterization of fetal keratinocytes, showing enhanced stem cell-like properties: a potential source of cells for skin reconstruction. Stem Cell Reports. 2014;3(2):324-338.

77. Dixit S, Baganizi DR, Sahu R, et al. Immunological challenges associated with artificial skin grafts: available solutions and stem cells for future design of synthetic skin. J Biol Eng. 2017;11:49.

78. Seo GY, Lim Y, Koh D, et al. TMF and glycitin act synergistically on keratinocytes and fibroblasts to promote wound healing and anti-scarring activity. Exp Mol Med. 2017;49(3):e302.

79. Walraven M, Talhout W, Beelen RHJ, et al. Healthy human second-trimester fetal skin is deficient in leukocytes and associated homing chemokines. Wound Repair Regen. 2016;24(3):533-541.

80. Wulf BC, Parent AE, Meleski MA, et al. Mast cells contribute to scar formation during fetal wound healing. J Invest Dermatol. 2012;132(2):458-465.

81. Wilgus TA, Wulf BC. The importance of mast cells in dermal scarring. Adv Wound Care (New Rochelle). 2014;3(4):356-365.

82. Chen L, Schrementi ME, Ranzer MJ, et al. Blockade of mast cell activation reduces cutaneous scar formation. PLoS One. 2014;9(1):e85226.

83. Hu M-M, Rennert RC, McArdle A, et al. The role of stem cells during scarless skin wound healing. Adv Wound Care (New Rochelle). 2014;3(4):304-314.

84. Li Q, Zhang C, Fu X. Will stem cells bring hope to pathological skin scar treatment? Cytotherapy. 2016;18(8):943-956.

85. Doi H, Kitajima Y, Luo L, et al. Potency of umbilical cord blood- and Wharton’s jelly-derived mesenchymal stem cells for scarless wound healing. Sci Rep. 2016;6:18844.

86. Fukutake M, Ochiai D, Masuda H, et al. Human amniotic fluid stem cells have a unique potential to accelerate cutaneous wound healing with reduced fibrotic scarring like a fetus. Hum Cell. 2019;32(1):51-63.

87. Wang X, et al. Fetal dermal mesenchymal stem-cell-derived exosomes accelerate cutaneous wound healing by activating notch signaling. Stem Cells Int. 2019;2019:2402916.

88. Zhao B, Zhang Y, Han S, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation. J Mol Histol. 2017(48):121-132.

89. Bodnar RJ, Satish L, Yates CC, et al. Pericytes: a newly recognized player in wound healing. Wound Repair Regen. 2016;24(2):204-214.

90. Bodnar RJ, Yang T, Rigatti LH, et al. Pericytes reduce inflammation and collagen deposition in acute wounds. Cytotherapy. 2018;20(8):1046-1060.

91. Morris MW, Allukian M, Herdrich BJ, et al. Modulation of the inflammatory response by increasing fetal wound size or interleukin-10 overexpression determines wound phenotype and scar formation. Wound Repair Regen. 2014;22(3):406-414.

92. Knipper JA, et al. Interleukin-4 receptor alpha signaling in myeloid cells controls collagen fibril assembly in skin repair. Immunity. 2015;43(4):803-816.

93. Pincha N, Hajam EY, Badarinath K, et al. PAI1 mediates fibroblast-mast cell interactions in skin fibrosis. J Clin Invest. 2018;128(5):1807-1819.

94. Nassar D, Letavernier E, Baud L, et al. Calpain activity is essential in skin wound healing and contributes to scar formation. PLoS One. 2012;7(5):e37084.

95. Ma K, Kwon SH, Padmanaban J, et al. Controlled delivery of a focal adhesion kinase inhibitor results in accelerated wound closure with decreased scar formation. J Invest Dermatol. 2018;138(11):2452-2460.

96. Zheng Z, James AW, Li C, et al. Fibromodulin reduces scar formation in adult cutaneous wounds by eliciting a fetal-like phenotype. Signal Transduct Target Ther. 2017;2:17050.

97. Zheng Z, Lee KS, Zhang X, et al. Fibromodulin-deficiency alters temporospatial expression patterns of transforming growth factor-beta ligands and receptors during adult mouse skin wound healing. PLoS One. 2014;9(6):e90817.

98. Mori R, Tanaka K, de Kerckhove M, et al. Reduced FOXO1 expression accelerates skin wound healing and attenuates scarring. Am J Pathol. 2014;184(9):2465-2479.

99. Sen CK, Ghatak S. miRNA control of tissue repair and regeneration. Am J Pathol. 2015;185(10):2629-2640.

100. Guo J, Lin Q, Shao Y, Rong L, Zhang D. miR-29b promotes skin proliferation of human hypertrophic scar fibroblasts via targeting Col1A1. Stem Cell Reports. 2019;32(1):51-63.

101. Li Q, Zhang C, Fu X. Will stem cells bring hope to pathological skin scar treatment? Cytotherapy. 2016;18(8):943-956.
104. Mu S, Kang B, Zeng W, et al. MicroRNA-143-3p inhibits hypertrophic scar formation by targeting connective tissue growth factor CTGF/CCN2 via the Akt/mTOR pathway. Mol Cell Biochem. 2016;416(1-2):99-108.

105. Zhao F, Lang H, Wang Z, et al. Human novel microRNA Seq:915_x4024 in keratinocytes contributes to skin regeneration by suppressing scar formation. Mol Ther Nucleic Acids. 2019;14:410-423.

106. Zhou X, Xie Y, Xiao H, et al. MicroRNA-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7. Biomed Pharmacother. 2018;100:184-190.

107. Shen W, Wang Y, Wang D, et al. miR-145-5p attenuates hypertrophic scar via reducing Smad2/Smad3 expression. Biochem Biophys Res Commun. 2020;521(4):1042-1048.

108. Zhu HY, Li C, Zheng Z, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145. Biochem Biophys Res Commun. 2015;459(1):49-53.

109. Gras C, Ratuszny D, Hadamitzky C, et al. miR-145 contributes to hypertrophic scarring of the skin by inducing myofibroblast activity. Mol Med. 2015;21:296-304.

110. Liu F, Chen WW, Li Y, Zhang QJ, Zheng QB. MiR-6836-3p promotes proliferation of hypertrophic scar fibroblasts by targeting CTGF. Eur Rev Med Pharmacol Sci. 2018;22(13):4069-4074.

111. Guo L, Xu K, Yan H, et al. MicroRNA expression signature and the therapeutic effect of the microRNA21 antagonist in hypertrophic scar via reducing Smad2/Smad3 expression. Mol Med Rep. 2017;15(3):1211-1221.

112. Kwan P, Ding J, Tredget EE. MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar. PLoS One. 2015;10(4):e0123054.

113. Li Y, Zhang J, Zhang W, et al. MicroRNA-192 regulates hypertrophic scar fibrosis by targeting SIP1. J Mol Histol. 2017;48(5-6):357-366.

114. Liu B, Guo Z, Gao W. MiR-181b-5p promotes proliferation and inhibits apoptosis of hypertrophic scar fibroblasts through regulating the MEK/ERK/p21 pathway. Exp Ther Med. 2019;17(3):1537-1544.

115. Wang R, Bai Z, Wen X, et al. MiR-152-3p regulates cell proliferation, invasion and extracellular matrix expression through by targeting FOXF1 in keloid fibroblasts. Life Sci. 2019;234:116779.

116. Xie C, Shi K, Zhang X, et al. MiR-1908 promotes scar formation post-burn wound healing by suppressing Ski-mediated inflammation and fibroblast proliferation. Curr Tissue Res. 2016;366(2):371-380.

117. Velázquez KT, Enos RT, Carlson MS, et al. miR155 deficiency aggravates high-fat diet-induced adipose tissue fibrosis in male mice. Physiol Rep. 2017;5(18):e13412.

118. Zhang J, Zhou Q, Wang H, et al. MicroRNA-130a has pro-fibroproliferative potential in hypertrophic scar by targeting CYLD. Arch Biochem Biophys. 2019;671:152-161.

119. Zhou Z, Shu B, Xu Y, et al. microRNA-203 modulates wounding and scar formation via suppressing Hes1 expression in epidermal stem cells. Cell Physiol Biochem. 2018;49(6):2333-2347.

120. Lyu L, Zhao YU, Lu H, et al. Integrated interaction network of microRNA target genes in keloid scarring. Mol Diagn Ther. 2019;23(1):53-63.

121. Li C, Bai Y, Liu H, et al. Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim Biophys Sin (Shanghai). 2013;45(8):692-699.

122. Li M, Wang J, Liu D, Huang H. High-throughput sequencing reveals differentially expressed IncRNAs and circRNAs, and their associated functional network, in human hypertrophic scars. Mol Med Rep. 2018;18(6):5669-5682.

123. Tu L, Huang QL, Fu S, et al. Aberrantly expressed long noncoding RNAs in hypertrophic scar fibroblasts in vitro: a microarray study. Int J Mol Med. 2018;41(4):1917-1930.

124. Zhu HY, Bai WD, Li C, et al. Knockdown of lncRNA-ATB suppresses autocrine secretion of TGF-beta2 by targeting ZNF217 via miR-200c in keloid fibroblasts. Sci Rep. 2016;6:24728.

125. Cao W, Feng Y. LncRNA XIST promotes extracellular matrix synthesis, proliferation and migration by targeting miR-29b-3p/ COL1A1 in human skin fibroblasts after thermal injury. Biol Res. 2019;52(1):52.

126. Jin J, et al. Long non-coding RNA HOXA11-AS accelerates the progression of keloid formation via miR-124-3p/TGFbetaR1 axis. Cell Cycle. 2020;19(2):218-232.

127. Jin J, Zhai H-F, Jia Z-H, et al. Long non-coding RNA HOXA11-AS induces type I collagen synthesis to stimulate keloid formation via sponging miR-124-3p and activation of Smad5 signaling. Am J Physiol Cell Physiol. 2019;317(5):C1001-c1010.

128. Wang Z, Feng C, Song K, et al. LncRNA-H19/miR-29a axis affected the viability and apoptosis of keloid fibroblasts through acting upon COL1A1 signaling. J Cell Biochem. 2020. [Epub ahead of print]. https://doi.org/10.1002/jcb.29649

129. Li J, Chen L, Cao C, et al. The long non-coding RNA LncRNA8975-1 is upregulated in hypertrophic scar fibroblasts and controls collagen expression. Cell Physiol Biochem. 2016;40(1-2):326-334.

130. Chen L, Li J, Li Q, et al. Overexpression of LncRNA AC067945.2 down-regulates collagen expression in skin fibroblasts and possibly correlates with the VEGF and Wnt signalling pathways. Cell Physiol Biochem. 2018;45(2):761-771.

131. Chen J, Zhou R, Liang Y, et al. Blockade of lncRNA-ASL-NC55088-enriched exosome generation in M2 macrophages by GW4869 dampens the effect of M2 macrophages on orchestrating fibroblast activation. FASEB J. 2019;33(11):12200-12212.

How to cite this article: Yin J-L, Wu Y, Yuan Z-W, Gao X-H, Chen H-D. Advances in scarless foetal wound healing and prospects for scar reduction in adults. Cell Prolif. 2020;53:e12916. https://doi.org/10.1111/cpr.12916